Evidence map›Paper›PMID 28416744›Full record

ArticleOncotarget2017

Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.

Henricus J M Handgraaf, Martin C Boonstra, Hendrica A J M Prevoo, Joeri Kuil, Mark W Bordo, Leonora S F Boogerd, Babs G Sibinga Mulder, Cornelis F M Sier, Maaike L Vinkenburg-van Slooten, A Rob P M Valentijn and 4 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05518071 (Intraoperative Near-infrared Fluorescence Imaging in Pancreatic- and Extrahepatic Bile Duct Tumors Using cRGD-ZW800-1 and Dedicated Imaging Systems), which is not on this map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05518071 phase2completednot on this mapstarted 2022, after this paper: background citation

Intraoperative Near-infrared Fluorescence Imaging in Pancreatic- and Extrahepatic Bile Duct Tumors Using cRGD-ZW800-1 and Dedicated Imaging Systems: A Phase II Feasibility Testing, Dose-ranging and Optimal Dose-(Interval) Selection Trial

TypeinterventionalSponsorLeiden University Medical CenterRan2022 to 2024Enrolled20ConditionsPancreas Adenocarcinoma, CholangiocarcinomaArmsCRGD-ZW800-1, Intraoperative near-infrared fluorescence imaging
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. The current status and future prospects for molecular imaging-guided precision surgery.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Henricus J M HandgraafDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Martin C BoonstraDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Hendrica A J M PrevooDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Joeri KuilDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Mark W BordoCuradel, LLC, Marlborough, MA, U.S.A.
Leonora S F BoogerdDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Babs G Sibinga MulderDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Cornelis F M SierDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Maaike L Vinkenburg-van SlootenDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
A Rob P M ValentijnDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Jacobus BurggraafCentre for Human Drug Research, Leiden, The Netherlands.
Cornelis J H van de VeldeDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
John V FrangioniCuradel, LLC, Marlborough, MA, U.S.A.
Alexander L VahrmeijerDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLCuradel (United States) · USLeiden University · NL

Funding

(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and TreatmentR01CA185457 · NCI · CURADEL, LLC · PI FRANGIONI, JOHN V · 2014 to 2017
$3.9M
Real-Time Flap Viability Monitoring during Facial Transplantation using SFDIR01DE022820 · NIDCR · CURADEL, LLC · PI FRANGIONI, JOHN V, LEE, BERNARD TRAVIS · 2013 to 2017
$3.0M
NCI NIH HHS R01 CA185457NIDCR NIH HHS R01 DE022820
6 · The paper itself

Abstract

Incomplete resections and damage to critical structures increase morbidity and mortality of patients with cancer. Targeted intraoperative fluorescence imaging aids surgeons by providing real-time visualization of tumors and vital structures. This study evaluated the tumor-targeted zwitterionic near-infrared fluorescent peptide cRGD-ZW800-1 as tracer for intraoperative imaging of multiple cancer types. cRGD-ZW800-1 was validated in vitro on glioblastoma (U-87 MG) and colorectal (HT-29) cell lines. Subsequently, the tracer was tested in orthotopic mouse models with HT-29, breast (MCF-7), pancreatic (BxPC-3), and oral (OSC-19) tumors. Dose-ranging studies, including doses of 0.25, 1.0, 10, and 30 nmol, in xenograft tumor models suggest an optimal dose of 10 nmol, corresponding to a human equivalent dose of 63 μg/kg, and an optimal imaging window between 2 and 24 h post-injection. The mean half-life of cRGD-ZW800-1 in blood was 25 min. Biodistribution at 4 h showed the highest fluorescence signals in tumors and kidneys. In vitro and in vivo competition experiments showed significantly lower fluorescence signals when U-87 MG cells (minus 36%, p = 0.02) or HT-29 tumor bearing mice (TBR at 4 h 3.2 ± 0.5 vs 1.8 ± 0.4, p = 0.03) were simultaneously treated with unlabeled cRGD. cRGD-ZW800-1 visualized in vivo all colorectal, breast, pancreatic, and oral tumor xenografts in mice. Screening for off-target interactions, cRGD-ZW800-1 showed only inhibition of COX-2, likely due to binding of cRGD-ZW800-1 to integrin αVβ3. Due to its recognition of various integrins, which are expressed on malignant and neoangiogenic cells, it is expected that cRGD-ZW800-1 will provide a sensitive and generic tool to visualize cancer during surgery.

Indexed as

AnimalsCell Line, TumorCyclooxygenase 2Disease Models, AnimalFeasibility StudiesFemaleHalf-LifeHT29 CellsHumansIntegrin alphaVbeta3Intraoperative PeriodMCF-7 CellsMiceMice, NudeNeoplasmsOptical Imagingcyclic arginine-glycine-aspartic acid peptideCyclooxygenase 2Integrin alphaVbeta3Peptides, CyclicPtgs2 protein, mouseQuaternary Ammonium CompoundsSulfonic AcidsZW800-1 compoundfluorescence-guided surgeryintegrinsin vivo diagnosispreclinical validationRGD

Identifiers

PMID28416744
PMCPMC5400565
OpenAlexW2589907317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.